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ABSTRACT 
 
 Breast cancer is the most common form of cancer affecting women in Malaysia. 
Conventional drug treatment for breast cancer, chemotherapy would destroy the cancer 
cells because of the medicine targets on rapidly dividing cells. However, healthy cells 
and tissues in blood, mouth, intestinal tract, nose, nails, vagina and hair also divide 
rapidly, they could be damaged. A more promising technology called transdermal patch 
has been introduced due to side effects are common expected results from conventional 
treatment. Therefore, the aim of this study was to treat breast cancer by delivering drug 
from transdermal patch precisely and safely to targeted cancer cell so that reducing the 
side effects and dosage of drug used. The objectives of this study were to determine the 
drug concentration at breast tumor, to investigate the relationship between drug 
diffusivity and drug delivery efficiency, and to evaluate the efficiency of drug delivery 
under other parameters (i.e. deepness of tumor, temporal and spatial placement of 
transdermal patch). Available software, COMSOL was used in this study. Drug 
concentrations that able to diffuse and reach tumor in breast were studied. The 
simulation results showed that there was optimal drug diffusivity for maximum 
concentration of drug reached tumor in breast. However, below and higher than this 
drug diffusivity optimal value, the delivery of drug concentration was poorer when the 
lesser. Production of microchannels in the skin by microneedle can increase the drug 
diffusivity and ensure delivery of pharmacologically effective concentration of drug to 
the targeted site, breast cancer cell. Deeper the tumor grown within breast, lesser drug‟s 
concentration could be diffused to it. However, this could be solved by changing the 
place of transdermal patch application. The nearer the spatial placement of transdermal 
patch to tumor growth in the breast on the breast skin increased the effectiveness of 
drug delivery to tumor. The longer the temporal placement resulted in higher drug 
concentration could be delivered to breast tumor. However, this constant concentration 
gradient only achieved for less than one month. After this, the concentration gradient 
would become zero. As a conclusion, the drug diffusivity, deepness of breast tumor, 
spatial and temporal placement of transdermal patch must be taken into account when 
engineering, constructing and applying the transdermal patch in order to achieve the 
maximum breast cancer treatment with reducing the undesired side effects.  
 
 
 
 
 
 
 
 
 
 
iii 
 
ABSTRAK 
 
 Kanser payudara merupakan jenis kanser yang paling utama di kalangan wanita 
di Malysia. Ubat rawatan konvensional untuk kanser payudara, kemoterapi akan 
menghancurkan sel-sel kanser kerana ubat target pada sel-sel yang membahagi dengan 
cepat. Namun, sel-sel dan rangkaian yang sihat dalam darah, mulut, saluran, usus 
hidung, kuku, vagina dan rambut juga membelah dengan cepat, mereka boleh 
dirosakkan. Satu teknologi yang lebih menjanjikan disebut patch transdermal telah 
diperkenalkan kerana kesan sampingan merupakan umum hasil daripada rawatan 
konvensional. Oleh itu, tujuan dari penelitian ini adalah untuk mengubati kanser 
payudara dengan menghantarkan ubat dari patch transdermal dengan tepat dan selamat 
pada sel kanser yang disasarkan supaya mengurangkan kesan sampingan dan dosis ubat 
yang digunakan. Objektif-objektif dari penelitian ini adalah untuk menentukan 
konsentrasi ubat pada tumor di payudara, mengkaji perhubungan antara keresapan ubat 
dengan keberkesanan penghantaran ubat, dan menilai keberkesanan penghantaran ubat 
dalam parameter yang berbeza seperti kedalaman tumor dalam payudara, penempatan 
spasial dan temporal patch transdermal pada kulit. Tersedia software, COMSOL 
digunakan dalam kajian ini. Ubat konsentrasi yang dapat menyebar dan mencapai tumor 
dalam payudara dipelajari. Keputusan simulasi menunjukkan bahawa ada ubat 
keresapan optimum untuk konsentrasi ubat maksimum capai pada tumor dalam 
payudara. Namun, di bawah atau di atas nilai keresapan ubat yang optimum ini, 
penghantaran konsentrasi ubat menjadi lemah ketika semakin berkurangan keresapan 
ubat. Produksi microchannels di kulit dengan microneedle dapat meningkatkan 
keresapan ubat dan memastikan penghantaran konsentrasi farmakologi ubat yang 
berkesan ke tempat yang disasarkan, sel kanser payudara. Semakin dalam pertumbuhan 
tumor dalam payudara, semakin berkurangan ubat dapat meresap ke tumor. Namun 
begitu, scenario ini dapat diatasi dengan menukarkan tempat menempatkan patch. 
Semakin dekat penempatan spasial patch transdermal pada pertumbuhan tumor dalam 
payudara pada kulit payudara meningkatkan keberkesanan penghantaran ubat untuk 
tumor. Semakin lama penempatan temporal menghasilkan kepekatan ubat yang boleh 
disampaikan untuk tumor payudara lebih tinggi. Namun, kecerunan konsentrasi ini 
hanya dapat dicapai kurang daripada satu bulan. Selepas ini, kecerunan konsentrasi ubat 
akan menjadi kosong. Sebagai kesimpulan, keresapan ubat, kedalaman pertumbuhan 
tumor dalam payudara, penempatan spasial dan temporal transdermal patch harus 
diperhitungkan sewaktu kejuruteraan, membina dan melaksanakan patch transdermal 
untuk mencapai rawatan kanser payudara maksimum dengan mengurangkan kesan 
sampingan yang tidak diingini. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
 This chapter presents the overview of the background for disease of breast 
cancer and breast cancer drug therapies. The problem statement of current 
technology is also stated in this chapter. The objectives of the study also presented in 
this chapter. The scope and importance of work are defined. Lastly, this chapter also 
outlines the organization of the thesis.    
 
 
1.1 BACKGROUND OF STUDY 
 
 Breast cancer is the most common form of cancer among women other than 
other skin cancer, and the number of cases for breast cancer is increased annually. 
About one in nineteen women in Malaysia are at risk. Breast cancer is also the 
leading cause of cancer-related death for women. In Peninsula Malaysia, the 
mortality rate per 100,000 showed an increase from 3.7 per 100,000 in 1982 to 5.8 
per 100,000 in 1990. However, since only one-third of deaths in Peninsula Malaysia 
were medically certified, the mortality rate from breast cancer was actually higher. 
(Yip, C. H. and Ng, E. H., 1996). 
  
 Generally, chemotherapy is the common drug therapy for breast cancer. 
Many anticancer drugs are designed to simply kill cancer cells. They are often in a 
semi-specific fashion because the anticancer drugs target on rapidly dividing cells. 
Similar to cancer cells, the normal cells in blood, mouth, intestinal tract, nose, nails, 
vagina and hair also divide rapidly. Consequently, the distribution of anticancer 
drugs in healthy organs or tissues is especially undesirable due to the potential for 
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severe side effects. This phenomenon greatly limits the maximal allowable dose of 
the drugs. However, low local drugs‟ concentration will cause less effect on 
destroying the cancer cells. Therefore, there is still a need for high or frequent drugs 
dosing. 
  
 To overcome such limitations, a new and more promising technology, 
transdermal technology has been introduced for breast cancer drug therapy. This 
application provides an alternative route for delivering drugs to cancer cells, which is 
through the largest organ of humans‟ bodies, skin. In this method, a transdermal 
patch is purposely engineered and constructed to allow the delivering of drugs 
precisely to the targeted cancer cells with fewer side effects. Site-specific drugs 
delivery is a concept that has the potential to increase local drugs‟ concentrations, 
and thereby produce more effective medicines with reducing the dosage of drugs 
used.  
   
1.2 PROBLEM STATEMENT 
 
 The new technology, transdermal patch allows the delivering of anticancer 
drugs to targeted cancer cell as effectively as possible without side effects and 
reducing the dosage of drugs used. However, transdermal application has limitation 
due to the remarkable barrier properties of the outermost layer of skin, stratum 
corneum. This layer is mainly consisted of lipids, has no blood flow, and thus plays a 
key role in limiting the diffusion of drugs to the bloodstream. For transdermal drugs 
delivery system to be effective, the drugs must obviously be able to penetrate this 
skin barrier and reach the targeted cancer cells. To achieve this, suitable modification 
has been made on the transdermal delivery system. It is hard to deny that drug 
diffusivity is a very important factor to be considered.  
 
1.3 OBJECTIVES 
 
 The aim of this study was to treat breast cancer by delivering drug from 
transdermal patch precisely to targeted cancer cells so that reducing the side effects 
and dosage of drugs used. This can be achieved by the following specific objectives: 
 1. To determine the drug concentration at breast tumor, 
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 2. To investigate the relationship between drug diffusivity and drug delivery 
     efficiency, and 
 3. To evaluate the efficiency of drug delivery under other parameters (i.e.  
     deepness of tumor, temporal and spatial placement of transdermal patch). 
  
1.4 RESEARCH SCOPE 
 
 This study mainly focused on the efficiency of drug delivery from 
transdermal patch, which was evaluated by response parameter, drug concentration 
successfully reaching at the breast tumor. The study was carried out by using 
COMSOL software. Before implementing the COMSOL software, data collection for 
drug diffusivity and breast volume were needed. After data collection, simulation 
was run by using COMSOL software. The simulation was conducted with identified 
independent variables (i.e. drug diffusivity, deepness of tumor, temporal and spatial 
placement of transdermal patch). Simulation produced with different parameters was 
saved for further analyses. Graphs that relate the drug concentration at breast tumor 
were also developed. From the developed graphs, the association between the 
efficiency of drug delivery and drug concentration could be made.  
  
1.5 RATIONALES AND SIGNIFICANCES 
 
 This study had the significance to do a new strategy on developing a more 
promising technology to treat breast cancer. This study also important for eliminate 
the side effects or toxicities caused by conventional drug therapies. This was 
replaced by the application of new technology, transdermal patch. The other 
significance was including reducing the drug dosage used for breast cancer treatment. 
Reduce side effects and drug dosage used, thereby decreasing the cost of breast 
cancer treatment. 
 
1.6 ORGANIZATION OF THESIS 
   
 This thesis is mainly delegated into five different chapters. In first chapter, 
the background of study, problem statement, objectives, scope and significances of 
project are reviewed in order to list out the tasks and act as a guideline for this study. 
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The statistic of breast cancer, skin structure, theoretical background, previous studies 
and some basic information related to the project title are detailed in the second 
chapter. Chapter 3 presents the methodology used from the starting until the end of 
the study, which including the material or instrument used for completing the study, 
designing the simulation and how to run the simulation. An overview of overall 
methodology that designated in a flow chart as guideline for task sequences also 
included in this chapter. 
 
 Chapter 4 shows the results obtained from the simulation. Several graphs 
made to preview the relationship between the drug concentration and time, which 
were resulting from different parameters also presented. At the end of this chapter, 
results, some of findings and the sources of errors that affect the simulation outcomes 
are discussed in details. The last chapter, chapter 5 states the conclusions of the 
study. Recommendations for improvement of the study in the future also are outlined 
in this chapter.  
  
 
 
CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
 This chapter includes the statistic of breast cancer, drug therapies of breast 
cancer, structure of skin, theories of transdermal application and some basic 
information related to the study. Studies on some recent patents related to the field of 
transdermal patch are also presented.  
 
 
2.1 OVERWIEW OF BREAST CANCER STATISTIC  
 
 The problem of cancer in Malaysia is in a growing trend, and breast cancer is 
the most common cancer among women. Over the years from 1993 to 2003, there 
were a total of 1818 breast cancer patients in the University Hospital. The number of 
breast cancer patients increased annually, with the highest recorded in 2003. This 
was 6 times the number of breast cancer patients in 1993 (Figure 2.1). 
 
 
Figure 2.1: Breast cancer in University Malaya Medical Centre, Kuala Lumpur  
         1993-2003, with total number of 1818 cases. 
 
Source: College Of Radiology Breast Health Information Centre (2008) 
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 Breast cancer formed 30% and 31.1% of newly diagnosed cancer cases in 
women in 2002 and 2003. This was followed by cancer of the cervix, which only 
formed 12% and 12.9% of total female cancers in 2002 and 2003 respectively 
(Figure 2.2). 
 
 
 
Figure 2.2: Percentage of different kinds of cancer in Malaysian women, in the year 
        of 2002 and 2003. 
 
Source: College Of Radiology Breast Health Information Centre (2008) 
 
 The number of deaths form breast cancer also showed an increasing trend, 
which were 260, 320 and 339 for the year of 1994, 1995 and 1998 respectively. And 
within these numbers, only 1/3 of all deaths in Malaysia were medically certified 
(Table 2.1). This indicated that the awareness of breast cancer among women still 
low and not effective enough. Within the detected women with breast cancer, only 
55.6% of Malaysian women presented with early stage breast cancer (Stage 0 – 1) 
compared with 72% of Singaporean women in 1990. (Yip, C. H. and Ng, E. H., 
1996) From the year of 1993 to 2004, there were 30-40% of the patients presented in 
the late stage and although women are now presenting with smaller tumours, the 
decrease in size is not significant. (College Of Radiology Breast Health Information 
Centre, 2008). 
 
Table 2.1: Deaths from cancers in Malaysia women for the years of 1994, 1995 and 
         1998. 
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Source: Vital Statistic Malaysia 
 
2.2 CONVENTIONAL BREAST CANCER DRUG THERAPY 
 
 The most common breast cancer drug therapy, also known as chemotherapy, 
in simplest sense, is a treatment with the aid of drugs that killing microorganisms or 
cancerous cells. The chemotherapy drugs can be swallowed by someone as tablets or 
capsules, or injected intravenously through the veins. When the drugs reach cancer 
cells, the drugs work by disrupting the growth of cancer cells.  
  
 However, when the drugs circulate in the blood, they not only reach cancer 
cells, but wherever they are in body. Many anticancer drugs are designed simply kill 
cancer cells. They have no the capability to distinguish between the cancer cells and 
normal cells. In contrast, they work by killing the cells that are actively growing and 
dividing into new cells.  Cancer cells do grow and divide much more often than 
normal cells because most normal cells grow and divide in a precise, orderly way.  
Thus, cancer cells are more likely to be killed by the chemotherapy drugs. However, 
there are still some normal cells do divide and grow rapidly such as cells in hair 
follicles, nails, mouth, intestinal tract and bone marrow. Chemotherapy drugs can 
unintentionally harm these other types of rapidly dividing cells. As a result, the 
distribution of anticancer drugs in healthy and normal cells is especially undesirable 
due to the potential for severe side effects.    
 
 The side effects caused are significantly depending on the types of drugs, 
drugs dosage used, how long the drugs are taken and how though of the own body of 
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the one who consuming these chemotherapy drugs. The possibilities of common side 
effects caused by some different kinds of anticancer drugs are discussed with details 
in the next sub-topic. 
 
2.2.1    DOCETAXEL  
 
 Docetaxel is one of the taxane drugs that were originally developed from the 
yew tree. Docetaxel is a man-made drug that was first made from the needles of the 
yew tree. It is known by its brand name, Taxotere. It works by stopping the cancer 
cells from separating into two new cells, so it blocks the growth of the cancer. 
Common side effects caused by this drug are as following (Cancer Health UK, 
2009):- 
 Have temporary drop in the number of blood cells made by the bone marrow. 
For example, a drop in white blood cells result a person with increased risk of 
getting an infection. When there is a dropping of red blood cells, a person 
will easy feel tired and breathless. Besides, bruising easily is another common 
side effect due to a drop in platelets.  
 Fatigue is the most disruptive side effect where tiredness often carries on 
after treatment has just ended. 
 Patients may experience fluid retention such as swelling of the hands and feet 
and resulting in weight gain and breathless. 
 Some people develop soreness, redness and peeling on the palms of the hands 
and soles of the feet. 
 Patients may have rash, hair loss, sore mouth, diarrhoe, numbness and 
tingling in hands and feets, allergic reaction during the infusion and 
fingernails become discoloured. 
 Docetaxel may have a harmful effect on a baby developing in the womb.  
 
2.2.2 DOXORUBICIN (ADRIAMYCIN) 
 
 Doxorubicin works by binding to the cancer cells‟ DNA and blocking an 
important enzyme called topo-isomerase II. This makes the DNA get tangled up and 
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the cancer cells cannot divide and grow. The common side effects associated with 
doxorubicin are listed below (Cancer Health UK, 2009):- 
 Have temporary drop in the number of blood cells made by the bone marrow. 
For example, a drop in white blood cells result a person with increased risk of 
getting an infection. When there is a dropping of red blood cells, a person 
will easy feel tired and breathless. Besides, bruising easily is another common 
side effect due to a drop in platelets.  
 Fatigue during and after treatment. 
 Feeling or being sick may be severe. 
 Urine may become a pink or red colour for one or two days after treatment. 
 Patients may have hair loss, sore mouth, sensitivity to sunlight, black or 
brown lines may appear in the creases of skin, watery eyes and conjunctivitis 
but very rare to happen. 
 A woman may stop or temporarily stop having periods, and loss of fertility. 
 Doxorubicin may have a harmful effect on a developing baby.  
 
2.2.3 HERCEPTIN (TRASTUZUMAB) 
 
 Herceptin is a monoclonal antibody. It targets a protein called HER2. This 
protein is found in roughly 25 to 30 percent of breast cancers. By interfering with 
this protein, this medicine can stop cancer cell growth. With this drug, the common 
side effects are:- 
 Breathing difficulties. 
 Chest pain or palpitations. 
 Cough. 
 Dizziness or fainting. 
 Fever or chills, sore throat. 
 Skin rash, itching or hives. 
 Swelling of the legs or ankles. 
 Usually weak or tired. 
 Loss of appetite. 
 Headache. 
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 Muscle aches. 
 Nausea. 
  
2.2.4 PACLITAXEL (TAXOL) 
 
 Paclitaxel is in a class of drugs known as taxanes. It slows or stops the growth 
of cancer cells in body. Side effects from paclitaxel are common, and include:- 
 Nausea and vomiting. 
 Loss of appetite. 
 Change in taste. 
 Thinned or brittle hair. 
 Pain in the joints of the arms or legs lasting 2-3 days. 
 Changes in the colour of the nails. 
 Tingling in the hands or toes. 
 
2.2.5 METHOREXATE (MAXTREX) 
 
 Methotrexate is similar to a normal body molecule called folinic acid, but has 
a slightly different in structure. So it stops some cells working properly. Cancer cells 
need to make and repair DNA to grow and multiply. Anti-metabolites often stop cells 
making and repairing DNA. Methotrexate also stops some normal cells working 
properly, causing side effects as following (Cancer Health UK, 2009):- 
 Have temporary drop in the number of blood cells made by the bone 
marrow. For example, a drop in white blood cells result a person 
with increased risk of getting an infection. When there is a dropping 
of red blood cells, a person will easy feel tired and breathless. 
Besides, bruising easily is another common side effect due to a drop 
in platelets.  
 Fatigue during and after treatment. 
 A patient may experience taste changes, mouth sores, diarrhoe, gritty 
eyes and hair loss or hair thinning. 
 This drug may harm a baby developing in the womb. 
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 Besides of individual chemotherapy drugs, there are some chemotherapy 
combinations of drugs used for killing cancer cells such as doxorubicin and 
cyclophosphamide (AC), methotrexate, mitozantrone and mitomycin (MMM), 
epirubicin, cyclophosphamide and fluoruocil (FEC) and the list goes on. These 
combinations are kwon as combination regimens and different combinations of drugs 
have different side effects. 
 
2.3 TRANSDERMAL APPLICATION  
  
 Transdermal patch is providing an effective alternative route for delivering 
drugs to cancer cells, which is through the largest organ of human bodies, skin. 
Transdermal delivery of medications was foreshadowed in earlier eras by the use of 
certain plasters and ointments. (Stanley, S., 2004) 
 
 Since the drugs are delivered directly from human‟s skin to bloodstream, it 
has provided a wide variety of advantages compared to chemotherapy. First of all, 
side effects associated with traditional delivery method could be eliminated due to 
site-specific delivery of drugs to the targeted site, cancer cells without circulating 
through the whole body like chemotherapy. The second benefit resulted from this 
shortened metabolic pathway of transdermal route is allowing for reduced 
pharmacological dosing. (Girish, C., 2006) Studies have shown that when 
formulations are delivered topically, as little as 5% of the drug can be make it to the 
cells where we need it when we taking a drug orally. This is because a large 
proportion of drug is destroyed and neutralized in stomach, intestine and liver before 
reaching bloodstream. On the other hands, transdermal technology ensures as much 
as 95% of a supplement reaches the cells it is needed. (Department of Pharmacology, 
University of Dublin) 
 
 Some other benefits of using transdermal application are including the 
transdermal patch provides the controlled release of drugs directly into the 
bloodstream through intact skin. By delivering a steady flow of drugs into the 
bloodstream for an extended period of time, transdermal system can avoid peak- and 
– effect of oral or injectable therapy and can enable more controlled effective 
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treatment. Furthermore, transdermal patch application is convenient to use because it 
offers multi-day dosing and is flexible to terminate the drug administration by simply 
removing the patch from skin when there is toxicity observed. Last but not least, 
patients who have difficulty with swallowing pills or receiving injections, patch 
offers an effective alternative for them. The pros of transdermal appliction over 
chemotherapy are summarized in the table below (Table 2.2). 
 
Table 2.2: Differences between transdermal application and chemotherapy. 
 
Chemotherapy Transdermal Application 
Form of delivery of drugs is oral route. Provides an alternative route for 
delivering drugs, which is through skin. 
Poor bioavaibility. Site-specific drug delivery to obtain high 
local drug concentration. 
Peaks and valleys in medication level. Permits constant dosing. 
A large proportion of drug are destroyed 
and neutralized in stomach, intestine and 
liver before reaching bloodstream. 
Low circulating drug concentration 
avoiding the risk of side effects. 
Gastrointestinal pathway, leading to a 
need for high and/or frequent dosing. 
 
Allows for reduced 
pharmacological dosing due to the 
shortened metabolic pathway of the 
transdermal route. 
Cost prohibitive and inconvenient. Convenient, particularly when patches 
are applied once every several days. 
As little as 5% of the drug can make it to 
the cells where we need it.  
As much as 95% of a supplement reaches 
the cells where it is needed.  
 
2.4 PATCH DESIGN 
 
 Generally, patches are composted of four main components such as (1) Liner 
that protects the patch during storage and will be removed when prior to use. (2) A 
compartment in which the drug itself is held, which is in direct contact with release 
liner. (3) Adhesive that serves to adhere the components of the patch together along 
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with adhering the patch to the skin. (4) A permeable membrane that controls the 
release of the drug into the skin. (5) Backing that acts as a protective seal that forms 
the external surface and protects the medication from the outer environment (Figure 
2.3).  
 
 
 
Figure 2.3: Components of transdermal patch, which consisted of five main key    
          elements such as liner, drug, adhesive, membrane and backing. 
 
Source: Shreeraj, S. (2008) 
 
 There are four main types of transdermal patches in market, which are single-
layer Drug-in-Adhesive, Multi-layer-Drug-in-Adhesive, Reservoir and Matrix. In the 
Single-layer-Drug-in-Adhesive, the drug is included directly within the skin-
contacting adhesive. The adhesive layer is responsible for the releasing of the drug, 
and serves to adhere the various layers together, along with the entire system to the 
skin. The adhesive layer is surrounded by a temporary layer and a backing. The 
Multi-layer Drug-in-Adhesive is almost similar where the drug is incorporated 
directly into the adhesive. But, this multi-layer system adds another layer of drug-in-
adhesive, usually separated by a membrane. In contrast, the Reservoir transdermal 
system design includes a liquid compartment containing a drug solution or 
suspension separated from the release liner by a semi-permeable membrane and 
adhesive. The adhesive component of the product can either be as a continuous layer 
between the membrane and the release liner or as a concentric configuration around 
the membrane. In Matrix type, the Matrix has a drug layer of a semisolid matrix 
containing a drug solution or suspension, which is in direct contact with the release 
14 
 
liner. The adhesive layer in this patch surrounds the drug layer partially overlaying it. 
(Yury, B., 2006) 
  
2.5 THEORY OF TRANSDERMAL DRUG DELIVERY SYSTEM 
 
 A transdermal drug delivery device, transdermal patch works in a very simply 
way. When the patient applies the patch to the skin, the medication is releasing form 
the vehicles and begins permeating through the skin into bloodstream at a rate 
regulated by the membrane. Once succeed to penetrate through the skin barrier, the 
drug will be uptake by the capillary network and finally reaches the targeted cancer 
cells. Lastly, activation of the pharmacological response to the cancer cells is 
happening. The whole process can be listed as below (Girish, C., 2006):- 
 1. Release of the medicament from the vehicle. 
 2. Penetration through the skin barrier. 
 3. Uptake of the drug by the capillary network in the dermal capillary layer. 
 4. Activation of the pharmacological response. (Banker, G.S. and Rhodes,    
     C.T., 1990)  
 
 In this study, the second step, penetration through the skin barrier was the 
main key element to be emphasized. In theory, this step is carried out through a 
passive diffusion process and it will be discussed in the coming sub-topic later. 
 
2.5.1 PENETRATION OF DRUG FROM PATCH THROUGH PASSIVE 
 DIFFUSION PROCESS 
  
 As introduced in the sub-topic above, the transportation of drug from patch to 
bloodstream is done through a passive diffusion process (Figure 2.4). In other words, 
a drug is applied in a relatively high dosage to the inside of a patch, which is worn on 
the skin for an extended period of time. Then, the drug is diffused into the body 
directly from transdermal patch across the skin barrier due to there is high 
concentration of drug on the patch and low concentration of drug in the bloodstream. 
The drug will keep diffusing into the blood for a long period of time, maintaining the 
constant concentration of drug in the blood flow.  
  
